Medifast Inc (MED) stock
Close on Nov 17, 2026Market cap $136.32MP/E –Yield 0.00%
Earnings
Medifast's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Medifast's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 16, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 26, 2026before the open | $72.00M | -19.5% | $1.57 | $0.19 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 3, 2026during market hours | $76.40M | -27.7% | -$0.28 | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 4, 2026during market hours | $76.00M | -34.3% | -$0.19 | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 17, 2026during market hours | $75.10M | -36.9% | -$1.65 | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 3, 2025during market hours | $89.40M | -36.2% | -$0.21 | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 4, 2025during market hours | $105.60M | -37.4% | $0.22 | – | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 28, 2025during market hours | $115.70M | -33.8% | -$0.07 | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 18, 2025during market hours | $119.00M | -37.7% | $0.07 | $0.10 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 4, 2024during market hours | $140.20M | -40.6% | $0.10 | $0.35 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 5, 2024during market hours | $168.60M | -43.1% | -$0.75 | $0.92 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 29, 2024during market hours | $174.70M | -49.9% | $0.76 | $0.66 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 20, 2024during market hours | $191.00M | -43.4% | $0.55 | $1.09 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 6, 2023during market hours | $235.90M | -39.6% | $2.12 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 7, 2023during market hours | $296.20M | -34.7% | $2.77 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 1, 2023during market hours | $349.00M | -16.4% | $3.67 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 21, 2023during market hours | $337.20M | -10.7% | $2.41 | $3.70 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022during market hours | $390.40M | -5.6% | $3.27 | $3.32 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 3, 2022during market hours | $453.30M | – | $3.42 | $3.87 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 2, 2022during market hours | $417.60M | – | $3.59 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 23, 2022during market hours | $377.80M | – | $2.91 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021during market hours | $413.40M | – | $3.56 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 4, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 2, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Medifast's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| revenue | Q4 FY2026 | $55.00M – $75.00M | – | New | Oct 26, 2026 |
| Adjusted EBITDA excluding interest incomenon-GAAP | Q4 FY2026 | $2.00M – $6.00M | – | New | Oct 26, 2026 |
| income per shareGAAP | Q4 FY2026 | $0.00 – $0.25 | – | New | Oct 26, 2026 |
| revenue | FY2026 | $280.00M – $300.00M | – | New | Oct 26, 2026 |
| revenue | FY2026 | $270.00M – $300.00M | $270.00M – $300.00M | Reaffirmed | Aug 3, 2026 |
| Adjusted EBITDA excluding interest incomenon-GAAP | FY2026 | $10.00M – $14.00M | – | New | Oct 26, 2026 |
| loss per shareGAAP | FY2026 | $1.80 – $2.05 | – | New | Oct 26, 2026 |
| loss per share | FY2026 | -$1.75 – -$0.25 | -$2.75 – -$1.55 | Raised | Aug 3, 2026 |
| loss per sharenon-GAAP | FY2026 | $0.45 – $0.70 | – | New | Oct 26, 2026 |
Guidance vs results
The last range Medifast gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | loss per share | -$0.65 – -$0.15 | $0.19 | Above range |
| Q3 FY2026 | Revenue | $60.00M – $80.00M | $72.00M | Within range |
| Q2 FY2026 | EPS (GAAP) | -$1.00 – -$0.50 | -$0.28 | Above range |
| Q2 FY2026 | Revenue | $60.00M – $80.00M | $76.40M | Within range |
| Q1 FY2026 | EPS (GAAP) | -$0.70 – -$0.15 | -$0.19 | Within range |
| Q1 FY2026 | Revenue | $65.00M – $80.00M | $76.00M | Within range |
| Q4 FY2025 | EPS (GAAP) | -$1.25 – -$0.70 | -$1.65 | Below range |
| Q4 FY2025 | Revenue | $65.00M – $80.00M | $75.10M | Within range |
| Q3 FY2025 | EPS (GAAP) | -$0.60 – $0.00 | -$0.21 | Within range |
| Q3 FY2025 | Revenue | $70.00M – $90.00M | $89.40M | Within range |
| Q2 FY2025 | Revenue | $85.00M – $105.00M | $105.60M | Above range |
| Q1 FY2025 | Revenue | $100.00M – $120.00M | $115.70M | Within range |
| Q4 FY2024 | diluted loss per share | -$0.65 – -$0.10 | $0.10 | Above range |
| Q4 FY2024 | Revenue | $100.00M – $120.00M | $119.00M | Within range |
| Q3 FY2024 | diluted loss per share | $0.05 – $0.70 | $0.35 | Within range |
| Q3 FY2024 | Revenue | $125.00M – $145.00M | $140.20M | Within range |
| Q2 FY2024 | diluted EPS | $0.05 – $0.40 | $0.92 | Above range |
| Q2 FY2024 | Revenue | $150.00M – $170.00M | $168.60M | Within range |
| Q1 FY2024 | diluted EPS | $0.25 – $0.95 | $0.66 | Within range |
| Q1 FY2024 | Revenue | $155.00M – $175.00M | $174.70M | Within range |
| Q3 FY2023 | EPS (GAAP) | $0.71 – $1.32 | $2.12 | Above range |
| Q3 FY2023 | Revenue | $220.00M – $240.00M | $235.90M | Within range |
| Q2 FY2023 | EPS (GAAP) | $1.32 – $1.44 | $2.77 | Above range |
| Q2 FY2023 | Revenue | $250.00M – $270.00M | $296.20M | Above range |
| Q1 FY2023 | EPS (GAAP) | $1.75 – $2.40 | $3.67 | Above range |
| Q1 FY2023 | Revenue | $300.00M – $320.00M | $349.00M | Above range |
Guidance history
Every forecast Medifast put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 26, 2026 | Adjusted EBITDA excluding interest income | Q4 FY2026 | $2.00M – $6.00M | New |
| Oct 26, 2026 | Adjusted EBITDA excluding interest income | FY2026 | $10.00M – $14.00M | New |
| Oct 26, 2026 | loss per share | FY2026 | $0.45 – $0.70 | New |
| Oct 26, 2026 | income per share | Q4 FY2026 | $0.00 – $0.25 | New |
| Oct 26, 2026 | loss per share | FY2026 | $1.80 – $2.05 | New |
| Oct 26, 2026 | revenue | Q4 FY2026 | $55.00M – $75.00M | New |
| Oct 26, 2026 | revenue | FY2026 | $280.00M – $300.00M | New |
| Aug 3, 2026 | loss per share | Q3 FY2026 | -$0.65 – -$0.15 | New |
| Aug 3, 2026 | loss per share | FY2026 | -$1.75 – -$0.25 | Raised |
| Aug 3, 2026 | revenue | FY2026 | $270.00M – $300.00M | Reaffirmed |
| Aug 3, 2026 | revenue | Q3 FY2026 | $60.00M – $80.00M | New |
| May 4, 2026 | loss per share | FY2026 | -$2.75 – -$1.55 | Reaffirmed |
| May 4, 2026 | loss per share | Q2 FY2026 | -$1.00 – -$0.50 | New |
| May 4, 2026 | revenue | FY2026 | $270.00M – $300.00M | Reaffirmed |
| May 4, 2026 | revenue | Q2 FY2026 | $60.00M – $80.00M | New |
| Feb 17, 2026 | loss per share | FY2026 | -$2.75 – -$1.55 | New |
| Feb 17, 2026 | loss per share | Q1 FY2026 | -$0.70 – -$0.15 | New |
| Feb 17, 2026 | revenue | FY2026 | $270.00M – $300.00M | New |
| Feb 17, 2026 | revenue | Q1 FY2026 | $65.00M – $80.00M | New |
| Nov 3, 2025 | diluted loss per share | Q4 FY2025 | -$1.25 – -$0.70 | New |
| Nov 3, 2025 | revenue | Q4 FY2025 | $65.00M – $80.00M | New |
| Aug 4, 2025 | diluted income/(loss) per share | Q3 FY2025 | -$0.60 – $0.00 | New |
| Aug 4, 2025 | revenue | Q3 FY2025 | $70.00M – $90.00M | New |
| Apr 28, 2025 | loss per share | Q2 FY2025 | -$0.55 – $0.00 | New |
| Apr 28, 2025 | revenue | Q2 FY2025 | $85.00M – $105.00M | New |
| Feb 18, 2025 | EPS | Q1 FY2025 | -$0.50 – $0.00 | New |
| Feb 18, 2025 | revenue | Q1 FY2025 | $100.00M – $120.00M | New |
| Nov 4, 2024 | diluted loss per share | Q4 FY2024 | -$0.65 – -$0.10 | New |
| Nov 4, 2024 | revenue | Q4 FY2024 | $100.00M – $120.00M | New |
| Aug 5, 2024 | diluted loss per share | Q3 FY2024 | $0.05 – $0.70 | New |
| Aug 5, 2024 | revenue | Q3 FY2024 | $125.00M – $145.00M | New |
| Apr 29, 2024 | diluted EPS | Q2 FY2024 | $0.05 – $0.40 | New |
| Apr 29, 2024 | revenue | Q2 FY2024 | $150.00M – $170.00M | New |
| Feb 20, 2024 | diluted EPS | Q1 FY2024 | $0.25 – $0.95 | New |
| Feb 20, 2024 | revenue | Q1 FY2024 | $155.00M – $175.00M | New |
| Nov 6, 2023 | diluted EPS | FY2023 | $8.65 – $9.55 | New |
| Nov 6, 2023 | effective tax rate | FY2023 | 20.5% – 21.5% | New |
| Nov 6, 2023 | revenue | FY2023 | $1.05B – $1.07B | New |
| Aug 7, 2023 | diluted EPS | Q3 FY2023 | $0.71 – $1.32 | New |
| Aug 7, 2023 | effective tax rate | Q3 FY2023 | 23% – 25% | New |
| Aug 7, 2023 | revenue | Q3 FY2023 | $220.00M – $240.00M | New |
| May 1, 2023 | diluted EPS | Q2 FY2023 | $1.32 – $1.44 | New |
| May 1, 2023 | effective tax rate | Q2 FY2023 | 24.5% – 26.25% | New |
| May 1, 2023 | revenue | Q2 FY2023 | $250.00M – $270.00M | New |
| Feb 21, 2023 | diluted EPS | Q1 FY2023 | $1.75 – $2.40 | New |
| Feb 21, 2023 | effective tax rate | Q1 FY2023 | 26% – 27% | New |
| Feb 21, 2023 | revenue | Q1 FY2023 | $300.00M – $320.00M | New |
| Nov 3, 2022 | non-GAAP diluted EPS | FY2022 | $11.61 – $13.05 | Lowered |
| Nov 3, 2022 | effective tax rate | FY2022 | 24% – 25% | Lowered |
| Nov 3, 2022 | revenue | FY2022 | $1.51B – $1.59B | Lowered |
| Aug 3, 2022 | non-GAAP diluted EPS | FY2022 | $12.70 – $14.10 | Lowered |
| Aug 3, 2022 | effective tax rate | FY2022 | 24.25% – 25.25% | Reaffirmed |
| Aug 3, 2022 | revenue | FY2022 | $1.58B – $1.66B | Lowered |
| May 2, 2022 | EPS | FY2022 | $14.60 – $16.05 | New |
| May 2, 2022 | effective tax rate | FY2022 | 24.25% – 25.25% | Reaffirmed |
| May 2, 2022 | revenue | FY2022 | $1.78B – $1.84B | Raised |
| Feb 23, 2022 | diluted EPS | FY2022 | $14.50 – $16.00 | New |
| Feb 23, 2022 | effective tax rate | FY2022 | 24.25% – 25.25% | New |
| Feb 23, 2022 | revenue | FY2022 | $1.72B – $1.79B | New |
| Nov 4, 2021 | EPS | FY2021 | $13.27 – $13.96 | New |
| Nov 4, 2021 | effective tax rate | FY2021 | 23.25% – 24.25% | New |
| Nov 4, 2021 | revenue | FY2021 | $1.51B – $1.53B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Medifast filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?